好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

Abstract Details

Efficacy and Safety of p48 Flow Diverters in the Treatment of Intracranial Aneurysms: A Systematic Review and Meta-analysis
Cerebrovascular Disease and Interventional Neurology
P9 - Poster Session 9 (5:00 PM-6:00 PM)
4-001
To systematically review and meta-analyze the efficacy and safety of p48 flow diverters in treating intracranial aneurysms, quantifying occlusion rates, complication rates, and comparing outcomes between devices with and without hydrophilic coating.

In the United States, effective treatment of intracranial aneurysms is vital since about 6 million people (nearly 1 in 50) harbor unruptured aneurysms, and rupture can result in subarachnoid hemorrhage with mortality rates approaching 40%.The p48 movable wire (MW) flow modulation devices are a group of novel low-profile flow diverters (FDs) that have recently been introduced for the management of small intracranial aneurysms (IAs). This study evaluates the current literature regarding the efficacy and safety of p48 in treating IAs.
A literature search was conducted using the PubMed, Embase, Scopus, and Web of Science databases. Studies evaluating the role of p48 FDs in IAs were included.
Twelve studies encompassing 312 individuals with 330 IAs were included. The meta-analysis revealed a pooled complete occlusion rate of 58% (95% CI: 40%-75%), a favorable outcome rate of 96% (95% CI: 86%-100%), and a morbidity rate of 1% (95% CI: 0%-3%). Regarding the complications, our findings showed a pooled intraprocedural rate of 7% (95% CI: 1%-16%), a postprocedural rate of 9% (95% CI: 6%-13%), an ischemic complication rate of 8% (95% CI: 5%-12%), a hemorrhagic complication rate of 3% (95% CI: 1%-5%), and an in-stent stenosis rate of 1% (95% CI: 0%-3%). The subgroup analysis comparing p48 MW and p48 MW with a hydrophilic coating (HPC) did not demonstrate significant differences between groups in outcomes and complications, except for hemorrhagic complications, which were higher in p48 MW than in p48 MW HPC devices (p48: 3% vs. p48 HPC: 0%, P = 0.04).
The p48 FDs represent novel therapeutic options in the management of IAs, associated with promising outcomes and low complication rates.
Authors/Disclosures
kimia didehvar, MD
PRESENTER 		Dr. didehvar has nothing to disclose.
Bardia Hajikarimloo, MD Dr. Hajikarimloo has nothing to disclose.
Ibrahim Mohammadzadeh, MD Dr. Mohammadzadeh has nothing to disclose.